Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States-Reference-Cited by-同舟云学术

Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States

Published:2024-09-03 Issue: Volume: Page:1-8
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Mohan Anjana¹,Damgacioglu Haluk²,Deshmukh Ashish A.²,Chen Hua¹,Wanat Matthew³,Essien Ekere James¹,Paranjpe Rutugandha¹,Fatima Bilqees¹,Abughosh Susan¹

Affiliation:

1. College of Pharmacy, University of Houston, Houston, TX, USA

2. Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA

3. Department of Pharmacy Practice and Translational Research, University of Houston, Houston, TX, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2024.2398487

Reference43 articles.

1. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.

2. Centers for Disease Control and Prevention (CDC). Atrial Fibrillation. 2020 [cited 2022 Jan]. Available from: https://www.cdc.gov/heartdisease/atrial_fibrillation.htm

3. Centers for Disease Control and Prevention (CDC). Leading Causes of Death. 2022 [cited 2022 Mar]. Available from: https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm

4. Stroke Prevention in Atrial Fibrillation in Older Adults: Existing Knowledge Gaps and Areas for Innovation: A Summary of an American Federation for Aging Research Seminar

5. Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association